Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: Btk inhibitors - Celgene

Next Previous
X
Search
Drug Profile

Research programme: Btk inhibitors - Celgene

Alternative Names: AVL -101; AVL-291; CC 90008

Latest Information Update: 04 Dec 2019

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Avila Therapeutics
  • Developer Celgene Corporation
  • Class Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Autoimmune disorders; Cancer

Most Recent Events

  • 20 Nov 2019 Celgene Corporation has been acquired by Bristol Myers Squibb
  • 11 Nov 2016 Pharmacodynamics data from in vitro and preclinical studies in Cancer presented at the 80th American College of Rheumatology and 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP-2016)
  • 11 Nov 2016 Pharmacodynamics data from a preclinical trial in Cancer presented at the 80th American College of Rheumatology (ACR-2016) and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ARHP-2016)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top